Evidence map›Paper›PMID 32631932›Full record

ArticleThorax2020

Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment.

Tommi Tervonen, Natalia Hawken, Nicola A Hanania, Fernando J Martinez, Sebastian Heidenreich, Ileen Gilbert

Open access · hybridAbstract read
In one paragraph

Article in Thorax, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Tommi TervonenPatient-Centered Research, Evidera, London, UK tommi.tervonen@evidera.com.ORCID 0000-0001-7303-500X
Natalia HawkenPatient-Centered Research, Evidera, London, UK.
Nicola A HananiaSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA.
Fernando J MartinezDivision of Pulmonary Medicine, Weill-Cornell Medical Center, Cornell University, New York City, New York, USA.
Sebastian HeidenreichPatient-Centered Research, Evidera, London, UK.
Ileen GilbertAstraZeneca, Wilmington, Delaware, USA.
AstraZeneca (United States) · USBaylor College of Medicine · USCornell University · USIthaka Harbors · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA variety of maintenance inhaler therapies are available to treat asthma and COPD. Patient-centric treatment choices require understanding patient preferences for the alternative therapies.

methodsA self-completed web-based discrete choice experiment was conducted to elicit patient preferences for inhaler device and medication attributes. Selection of attributes was informed by patient focus groups and literature review.

resultsThe discrete choice experiment was completed by 810 patients with asthma and 1147 patients with COPD. Patients with asthma most valued decreasing the onset of action from 30 to 5 min, followed by reducing yearly exacerbations from 3 to 1. Patients with COPD most and equally valued decreasing the onset of action from 30 to 5 min and reducing yearly exacerbations from 3 to 1. Both patients with asthma and patients with COPD were willing to accept an additional exacerbation in exchange for a 15 min decrease in onset of action and a longer onset of action in exchange for a lower risk of adverse effects from inhaled corticosteroids. Patients with asthma and COPD valued once-daily over twice-daily dosing, pressurised inhalers over dry powder inhalers and non-capsule priming over single-use capsules, although these attributes were not valued as highly as faster onset of action or reduced exacerbations.

conclusionsThe most important maintenance inhaler attributes for patients with asthma and COPD were fast onset of symptom relief and a lower rate of exacerbations. Concerns about safety of inhaled corticosteroids and device convenience also affected patient preferences but were less important.

Indexed as

Dry Powder InhalersMetered Dose InhalersPatient PreferenceAdolescentAdultAgedAsthmaChoice BehaviorEquipment DesignFemaleFocus GroupsHumansInterviews as TopicMaintenance ChemotherapyMaleMiddle AgedasthmaCOPD exacerbationsinhaler devices

Identifiers

PMID32631932
PMCPMC7476258
OpenAlexW3038237481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.